Table 3.
SUCRA of network meta-analysis in multiple interventions at 3 months and 6 months.
| TA | IVB | LP | Placebo | TA+LP | DEX | IVB+TA | DEX+LP | IVR | IVA | |
|---|---|---|---|---|---|---|---|---|---|---|
| BCVA-3 Month | 64.47% | 63.90% | 39.39% | 6.09% | 66.36% | 82.24% | 94.09% | 23.95% | 9.22% | – |
| BCVA-6 Month | 53.80% | 75.28% | 5.70% | 7.63% | 24.73% | 98.82% | 43.19% | 53.52% | 84.32% | – |
| CMT-3 Month | 49.90% | 16.00% | 33.26% | 0.11% | 73.11% | 44.37% | 94.41% | 88.86% | – | – |
| CMT-6 Month | 47.91% | 53.00% | 6.70% | 12.80% | 36.09% | 89.80% | – | 68.80% | – | 70.87% |
*TA, intravitreal triamcinolone; IVB, intravitreal bevacizumab; LP, laser, macroscopic laser, grid laser and focal/grid laser; TA+LP, intrareal triamcinolone combined with laser; DEX, intravitreal dexamethasone; IVB+TA, intravitreal bevacizumab combined with triamcinolone; DEX+LP, intrareal dexamethasone combined with laser; IVR, intravitreal ranibizumab; IVA, intravitreal affiliation.